Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
32 patients who underwent follow-up endoscopy during ongoing treatment, improvement was confirmed in 25 patients, and no cases exhibited unresolved gastritis beyond 18 weeks.
I · Intervention 중재 / 시술
endoscopy during first-line zolbetuximab-containing chemotherapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Early-onset transient gastritis frequently occurred following zolbetuximab-containing therapy and was significantly associated with anorexia and hypoalbuminemia. A deeper understanding of gastritis underlying unique GI toxicities may provide insight into effective management.
[BACKGROUND] Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), plus chemotherapy has become a standard treatment for CLDN18.2-positive advanced gastric cancer and is frequently as
- p-value P = 0.005
- p-value P = 0.012
APA
Yamamoto K, Owaki Y, et al. (2025). Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.. ESMO open, 10(10), 105805. https://doi.org/10.1016/j.esmoop.2025.105805
MLA
Yamamoto K, et al.. "Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.." ESMO open, vol. 10, no. 10, 2025, pp. 105805.
PMID
41033281
Abstract
[BACKGROUND] Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), plus chemotherapy has become a standard treatment for CLDN18.2-positive advanced gastric cancer and is frequently associated with early-onset gastrointestinal (GI) toxicities. While zolbetuximab-induced gastritis has been observed in preclinical studies, it has not been previously reported in patients.
[PATIENTS AND METHODS] We retrospectively analyzed patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-positive, advanced gastric or gastroesophageal junction cancer who underwent endoscopy during first-line zolbetuximab-containing chemotherapy. Patients who had undergone prior total gastrectomy were excluded. We evaluated associations between gastritis and clinical outcomes including GI toxicities and serum albumin level.
[RESULTS] Among 58 eligible patients, gastritis was observed in 52 (89.7%) at a median of 7.8 weeks after treatment initiation. Characteristic endoscopic findings included mucosal erythema (100%), white exudate (63.4%), edema (28.8%), and erosions or ulcerations (26.9%). The distribution of gastritis was predominantly diffuse (76.9%) rather than scattered (23.1%), commonly involving multiple gastric regions (90.4%). Patients with diffuse gastritis experienced significantly higher rates of any-grade anorexia compared with those without gastritis (97.5% versus 50.0%, P = 0.005) and more profound serum albumin decline [median decrease -1.2 g/dl, interquartile range (IQR) -1.525 to -0.9 g/dl versus -0.7 g/dl, IQR -0.8 to -0.6 g/dl; P = 0.012]. No patients discontinued treatment due to gastritis. Among 32 patients who underwent follow-up endoscopy during ongoing treatment, improvement was confirmed in 25 patients, and no cases exhibited unresolved gastritis beyond 18 weeks.
[CONCLUSIONS] Early-onset transient gastritis frequently occurred following zolbetuximab-containing therapy and was significantly associated with anorexia and hypoalbuminemia. A deeper understanding of gastritis underlying unique GI toxicities may provide insight into effective management.
[PATIENTS AND METHODS] We retrospectively analyzed patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-positive, advanced gastric or gastroesophageal junction cancer who underwent endoscopy during first-line zolbetuximab-containing chemotherapy. Patients who had undergone prior total gastrectomy were excluded. We evaluated associations between gastritis and clinical outcomes including GI toxicities and serum albumin level.
[RESULTS] Among 58 eligible patients, gastritis was observed in 52 (89.7%) at a median of 7.8 weeks after treatment initiation. Characteristic endoscopic findings included mucosal erythema (100%), white exudate (63.4%), edema (28.8%), and erosions or ulcerations (26.9%). The distribution of gastritis was predominantly diffuse (76.9%) rather than scattered (23.1%), commonly involving multiple gastric regions (90.4%). Patients with diffuse gastritis experienced significantly higher rates of any-grade anorexia compared with those without gastritis (97.5% versus 50.0%, P = 0.005) and more profound serum albumin decline [median decrease -1.2 g/dl, interquartile range (IQR) -1.525 to -0.9 g/dl versus -0.7 g/dl, IQR -0.8 to -0.6 g/dl; P = 0.012]. No patients discontinued treatment due to gastritis. Among 32 patients who underwent follow-up endoscopy during ongoing treatment, improvement was confirmed in 25 patients, and no cases exhibited unresolved gastritis beyond 18 weeks.
[CONCLUSIONS] Early-onset transient gastritis frequently occurred following zolbetuximab-containing therapy and was significantly associated with anorexia and hypoalbuminemia. A deeper understanding of gastritis underlying unique GI toxicities may provide insight into effective management.
MeSH Terms
Humans; Stomach Neoplasms; Female; Male; Gastritis; Middle Aged; Retrospective Studies; Aged; Claudins; Adult
같은 제1저자의 인용 많은 논문 (5)
- Complex t(8;14;18)(q24;q32;q21) Together With Novel t(3;6)(q27;p23) in Triple-Hit High-Grade B-Cell Lymphoma Showing Burkitt-Like Cytology.
- Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents.
- Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond.
- Defining Low Muscle Mass in Cancer Patients: Sex-Specific Computed Tomography-Derived Cutoff Values and Survival Impact-A Multicenter Cohort Study.
- Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.